最新研报
共 12,368 份研报 · 国内 7,612 · 国外 4,009 · 全库按发布时间排序
Solutions(7202.SE)2026年第三季度:销售额超出指引,同比增长10%;2026财年增长存在轻微上行风险
Solutions (7202.SE) 3Q26: Sales ahead of guidance at +10%; slight upside risk to FY26 growth
花旗·2026-10-26·12 页·其它
NOBA Bank Group(NOBA.ST):模型更新
NOBA Bank Group (NOBA.ST): Model Update
花旗·2026-10-26·12 页·其它
IDEAYA生物科学公司(IDYA.O):IDE849二线治疗17.4个月中位总生存期及全球安全性更新进一步强化其DLL3 ADC的竞争定位
IDEAYA Biosciences Inc (IDYA.O): IDE849's 17.4-Month 2L mOS and Global Safety Update Further Strengthen Competitive DLL3 ADC Profile
花旗·2026-10-26·11 页·美股
Centrica PLC(CNA.L):天然气管网并购前景如何?
Centrica PLC (CNA.L): Gas network M&A on the horizon?
花旗·2026-10-26·13 页·其它
Arrivent Biopharma(AVBP.O):CDH17在转移性结直肠癌中显著超越约30%的ORR基准,未来与贝伐珠单抗联合有望进一步提升ORR
Arrivent Biopharma Inc. (AVBP.O): CDH17 Handily Beats ~30% ORR Bar in mCRC, Future Combo With Bev Positioned to Push ORR Higher
花旗·2026-10-26·13 页·美股
A2牛奶公司(A2M.AX):H&H季度表现支持a2的战略布局
The A2 Milk Company Ltd (A2M.AX): H&H quarterly supports a2's strategy
花旗·2026-10-26·13 页·其它
中集来福士:烟台船厂投资者日核心要点
CIMC Raffles: Key takeaways from Investor Day at Yantai Shipyard
高盛·2026-10-26·6 页·港股
中国光伏:盈利拐点追踪(2026年10月)——成本上行致硅片/玻璃盈利恶化,多晶硅减产难阻库存累积
China Solar: Tracking Profitability Inflection — Oct-26: Profitability deteriorated in Wafer/Glass due to higher cost; Poly inventory rises despite production cuts
北京高华证券·2026-10-26·9 页·电气设备
潍柴动力(000338.SZ/2338.HK):向AI数据中心发电增长曲线迁移
Weichai Power (000338.SZ/2338.HK): Transitioning to AIDC power generation growth
高盛·2026-10-26·11 页·A股
2026年三季度业绩回顾:内销保持稳定,出口逐步回暖;维持"买入"评级
ZHEJIANG SUPOR CO. (002032.SZ): 3Q26 Earnings Review: Stable domestic and recovering export; Buy
北京高华证券·2026-10-26·8 页·A股
思源电气(002028.SZ):2026年三季度营业利润符合预期,一次性损益致净利润偏低,尽管面临监管挑战美国订单仍持续流入
Sieyuan Electric (002028.SZ): First Take: 3Q26 OP in line, NP below on one-offs, with continued US order intakes despite regulatory
北京高华证券·2026-10-26·10 页·A股
润泽科技(300442.SZ):简评:AI资本开支激增将加速高ROIC基建转型;2026年三季度收入确认时点因素导致业绩不及高盛预期
Range Intelligent (300442.SZ): First Take: AI Capex Surge to Accelerate Higher-ROIC Infra Transformation; 3Q26 Missed GSe on Sales Timing
北京高华证券·2026-10-26·8 页·创业板
培生(PSON.L):2026年前9个月业绩审视:业绩稳健,各板块趋势分化但集团整体预测基本维持不变,聚焦业务重组
Pearson (PSON.L): 9M26 results review: Solid print with group estimates broadly unchanged despite mixed segment trends; focus on re-segmentation
高盛·2026-10-26·11 页·其它
诺华(NOVN.S):2026年多伦多多发性硬化症大会公布remibrutinib数据后,多发性硬化领域KOL专家会核心要点
Novartis (NOVN.S) Takeaways from our Multiple Sclerosis KOL call following remibrutinib data presentation at MSToronto 2026
高盛·2026-10-26·14 页·其它
纽蒙特(NEM.US):2026年三季度成本管控超预期,彰显组合弹性与运营优势,维持“买入”评级
Newmont Corp. (NEM): 3Q26: Cost outperformance highlights portfolio optionality and recent operational excellence; Buy
高盛·2026-10-26·20 页·美股
宁德时代(300750.SZ/3750.HK):拓展电芯以外的能源解决方案
CATL (300750.SZ/3750.HK): Expanding energy solutions beyond battery cells
北京高华证券·2026-10-26·16 页·创业板
科伦博泰生物(6990.HK):TroFuse-005研究标志着sac-TMT取得首项全球III期胜利
Kelun Biotech (6990.HK): TroFuse-005 marks the first global ph3 win for sac-TMT
北京高华证券·2026-10-26·8 页·港股
科伦博泰(6990.HK):OptiTROP-Lung06提供关键去风险数据,疗效显著优于帕博利珠单抗/化疗
Kelun Biotech (6990.HK): OptiTROP-Lung06 provides key de-risk data with compelling survival win over pembro/chemo
北京高华证券·2026-10-26·7 页·港股
劲方医药(2595.HK):GFH276临床首秀鼓舞人心,支持其作为泛RAS骨干疗法的进一步探索
GenFleet Therapeutics (2595.HK): Encouraging clinical debut of GFH276 supports further exploration as pan-RAS backbone
北京高华证券·2026-10-26·6 页·港股
寒武纪(688256.SH):2026年三季度环比增长延续;2028年前收入维持三位数增长;维持"买入"评级
Cambricon (688256.SS): 3Q26 sequential increase continues; revenues to grow at triple digits through 2028; Buy
高盛·2026-10-26·9 页·科创板
显示 2361 - 2380 条,共 12,368 条